Company History

2011 | 2010 | 2009 | 2008 | 2007 | 2005 | 2004 | 2003 | 2002 | 2001

2011

APRIL 2011

• Selexis goes social. Company launches Facebook and Twitter pages.

MARCH 2011

• Selexis Completes Sequencing of the Selexis SURE CHO-M Genome
• Selexis Celebrates 10 Years of Innovation
• Selexis Launches SUREvariant screening™ Service

FEBRUARY 2011

• Selexis Doubles Cell line development Laboratory Space in Geneva, Switzerland

2010

•

2009

MARCH 2009

• Selexis Launches Biosimilar Cell line development Program

> back to top

2008

• Artelis and Selexis report record antibody production levels in CHO cells of over 31 grams per liter

> back to top

2007

APRIL 2007

• Selexis Establishes US Subsidiary outside of Boston, MA

FEB 2007

• Selexis Expands European Production and Business Operations with new facilities and staff.

> back to top

2005

JULY 2005

• Opening of the new R&D facility in Plan-les-Ouates.

APRIL 2005

• Selexis started the construction of its new R&D facility in Geneva and starts recruiting highly qualified personnel.

> back to top

2004

MARCH 2004

• The company closed its second round of private financing.

JANUARY 2004

• Selexis started the transfer of Selexis Genetic Elements II to all its new partners.

> back to top

2003

DECEMBER 2003 Selexis filed a new patent, called Selexis Genetic Elements II, based on a novel aspect of its technology platform. It is based on two novel and patent-protected principles: human MAR DNA sequences and new transfection procedures.

JUNE 2003

• Selexis moved its headquarters in Plan-les-Ouates, Geneva, Switzerland.

APRIL 2003

• Selexis entered into an agreement to acquire the intellectual property rights from the University of Lausanne.

FEBRUARY 2003

• The company closed its first round of private financing.

> back to top

2002

SEPTEMBER 2002

• Igor Fisch was awarded the NETS 2002 Best Prize.

JUNE 2002

• Dr. Igor Fisch was awarded a loan from the FIT (Fondation pour l’Innovation Technologique).

> back to top

2001

MARCH 2001

• Selexis SA was founded as a spin-out of the University of Lausanne by Dr. Igor Fisch and Prof. Nicolas Mermod. The company started hiring highly qualified people.
• Prof. Nicolas Mermod and Dr. Igor Fisch received seed financing from the CTI (Commission pour la Technologie et l’Innovation, Berne).
• Igor Fisch was awarded the De Vigier prize for the best Swiss biotech business idea of the Year 2000.

> back to top